<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100632</url>
  </required_header>
  <id_info>
    <org_study_id>GEREMS0310</org_study_id>
    <secondary_id>Version 01 - March 11, 2010</secondary_id>
    <nct_id>NCT01100632</nct_id>
  </id_info>
  <brief_title>Effectiveness Evaluation of Panax Ginseng, Vitamins and Minerals in Improvement of Stress and Fatigue</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <brief_summary>
    <textblock>
      We hope that with the drug, patients obtain reduced levels of stress and fatigue, according
      to the scales that we use in the study. Hopefully the results of the treated group are
      significantly higher than the control group (placebo).
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of stress and fatigue</measure>
    <time_frame>14 and 28 days</time_frame>
    <description>Stress: ISS Scale will be assessed by the scale - Inventory of Symptoms of Stress in the time selection / screening, 14 and 28 days ± 2 days of treatment.
Fatigue: FSS Scale will be assessed by the scale - Fatigue Severity Scale Selection in The Times / Triage, 14 and 28 days ± 2 days of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life and Sexual Function</measure>
    <time_frame>14 and 28 days</time_frame>
    <description>c) Quality of life: the quality of life of patients will be assessed using the Short Form 36 questionnaire (SF-36) during the period included 14 and 28 days ± 2 days of treatment.
d) Sexual function: evaluation of possible changes in libido or sexual performance that this drug will develop will be made by direct questioning by the doctor to the patient inclusion period 14 and 28 days ± 2 days of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Reduction of Stress and Fatigue</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the combination of Panax ginseng, vitamins and minerals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ginseng, vitamins, minerals</intervention_name>
    <description>2 capsules per day</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo - Gelatin capsule</intervention_name>
    <description>2 capsules per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agree with all study procedures, signing the IC in two ways;

          -  Patients older than 18 years, male or female, regardless of ethnicity or social class;

          -  Presence of mild to moderate stress, confirmed with the Stress Symptom Inventory
             (ISS);

          -  Presence of staff fatigue with a score greater than 36 according to the Fatigue
             Severity Scale (FSS).

        Exclusion Criteria:

        Constitute exclusion criteria of the study:

          -  Participation in clinical trials in the 12 months preceding the survey;

          -  Current treatment with drugs that are stimulants or central nervous system depressants
             such as hypnotics, anxiolytics, antipsychotics, antidepressants, statins and muscle
             relaxants;

          -  Alternative therapies that scientifically, or have no influence in the tables of
             stress or fatigue as color therapy, acupuncture or relaxing massages;

          -  Treatment psychotherapeutic medication or not;

          -  Current treatment or prediction of treatment with oral anticoagulants (due to
             interaction with the tocopherol);

          -  Women who are pregnant or lactating;

          -  Patients with lactose intolerance;

          -  Patients allergic to soy or peanuts;

          -  chronic renal failure;

          -  Patients using other multivitamins or individual vitamins such as vitamin D and / or
             A.

          -  Chronic alcoholism;

          -  Patients with clinical diagnosis of diseases causing severe chronic pain or adversely
             affect the clinical interpretation as fibromyalgia, multiple sclerosis, neuropathies
             and myopathies;

          -  Patients with hypothyroidism or hyperthyreosis diagnosed clinically;

          -  Patient history and physical examination suggestive of severe hepatorenal failure;

          -  Patients with decompensated diabetes mellitus (fasting glucose above 180 mg / dL);

          -  Patients undergoing treatment for cancer;

          -  Amendment of the routine of life during the study as early vacation or suspected
             change in working hours;

          -  Patients with complaints of excessive sleepiness caused by organic disease such as
             sleep apnea and morbid obesity (BMI above 35);

          -  History of hypersensitivity to any component of the product under investigation;

          -  Any finding of clinical observation (clinical history or physical examination) that is
             interpreted by the physician investigator as a risk to the patient's participation in
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>October 26, 2010</last_update_submitted>
  <last_update_submitted_qc>October 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Frederico</name_title>
    <organization>LAL Clinica Pesquisa e Desenvolvimento Ltda</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

